Benefits of Automated Diabetic Retinopathy Screening : A Discussion with Lauren Patty Daskivich, MD
Channel: Eyenuk, Inc.
Date: 2018-09-21

Benefits of Automated Diabetic Retinopathy Screening : A Discussion with Lauren Patty Daskivich, MD, director of Ophthalmology and Eye Health Program in Los Angeles County's Department of Health Services.

Eyenuk, Inc. in discussion with Lauren Patty Daskivich, MD (Los Angeles County). Topics: Diabetic retinopathy, the benefits of automated screening, and EyeArt™ by Eyenuk. 

Dr. Daskivich founded a teleretinal diabetic retinopathy screening program in Los Angeles County, now running in 14 primary care clinics across Los Angeles County. They screen 75-100 patients per day. This translates to 300-400 patients per week.

This has made a big difference for streamlining the process and efficiently triaging patients that have more severe disease and need expedited treatment, so that they can get help faster.

She states, "Any way in which a system such as ours can provide the same or higher quality of care with lesser manpower resources, is very effective for our large system across LA County. So a robust, reliable, effective automated screening program would allow us to provide the same or higher quality of care for the same amount or even less resources."

She goes on to say, "Based on the robust studies and the study numbers we have recently seen, EyeArt certainly seems like an automated software that will provide the resource saving mechanism that we really need to further our care of our patients in the diabetic population across Los Angeles county and really strengthen our teleretinal program so we can focus our resources in the areas where we need it most."

She adds, "Since EyeArt already seamlessly integrates with EyePACS, this is a really important piece for us in our system. (It) is having something we can standardize and spread across all of our systems."

We'd like to note that EyeArt has been evaluated in a study with over 100,000 consecutive patient cases, demonstrating sensitivity and specificity of over 91% when screening for referable diabetic retinopathy. Details of the study can be viewed here: https://iovs.arvojournals.org/article.aspx?articleid=2638442

Visit http://www.eyenuk.com for more information about EyeArt™.

EyeArt™ has been cleared for sales as a Class IIa medical device by EU and as a Class 2 medical device by Health Canada.
In the United States, EyeArt™ is limited by federal law to investigational use only and is not available for sale.  
 
Connect with us here:

https://www.linkedin.com/company/eyenuk-llc
https://www.facebook.com/eyenuk
https://twitter.com/eyenukinc
https://eyenuk.tumblr.com

Los Angeles County Department of Public Health:

http://publichealth.lacounty.gov/

 #Eyenuk #EyeArt #DRscreeningSoftware #DiabeticRetinopathy #diabeticretinopathyscreening #eyescreening